Definitive Contract 75N93020C00049
Award Date
9/1/20
Potential Completion Date
2/28/25
Potential Value
$7.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
University Of Massachusetts
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Worcester, MA 01655, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, HHSN272201600011C, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the University of Massachusetts Medical School (UMMS) for "STAGED VACCINE DEVELOPMENT". The $17,298,573.00 cost-no-fee contract does not have a set-aside designation. Under this contract, UMMS serves as the prime contractor and has subcontracted a portion of the work to the University...
This federal contract award, with an ID of HHSN272201300012I|75N93019F00131, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Alabama at Birmingham (UAB) for the development of a protocol, clinical trial implementation, closeout, and analysis of a Phase 2 clinical trial to evaluate the efficacy of RMENB+OMV NZ (Bexsero, GSK) in preventing N. gonorrhoeae infection. The contract, which does not have a set-aside designation, has a total ceiling...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIH NIAID) awarded a $21,640,423 cost-plus-fixed-fee definitive contract to Versatope Therapeutics Inc., a for-profit biotechnology company located in Lowell, Massachusetts. The contract was awarded in September 2019 under the Broad Agency Announcement 2018 (BAA2018) program to advance the development of recombinant outer membrane vesicle-based vaccines for infectious diseases such as malaria. The contract...
The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) has awarded a $6,000,000, 5-year cost-reimbursement contract to the University of Massachusetts Medical School (UMMS) for research on T cell immune epitopes associated with infectious diseases, autoimmune diseases, and transplant outcomes. The contract, which is not set-aside, is part of NIAID's effort to support multi-disciplinary teams focused on large-scale discovery and validation...
The University of Massachusetts Medical School Grants and Contracts Administration Division (doing business as Umms) was awarded a $16,060 purchase order by the National Institutes of Health's National Human Genome Research Institute to provide adenovirus-associated virus preparations in support of academic research. As the prime contractor, Umms will deliver the requested biological products for use at its Worcester, Massachusetts location under a firm fixed price contract running from August...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to the University of Massachusetts Medical School (UMass Medical) for the purchase of a 7 mg vial of the CD3 immunotoxin PR-0307 at a firm fixed price of $7,000.00. The award has no set-aside designation and was made as a purchase order on August 5, 2014, with a completion date of September 3, 2014. UMass Medical, which operates as a...
This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $795,403.00 contract is a delivery order awarded under an existing Indefinite Delivery Vehicle (IDV) for "Advanced Bioscience Laboratories Mucosal Vaccine Technologies". The contract is cost-plus-fixed-fee in type...
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This is a $18,576,013.05 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant infections, and emerging infectious diseases under Broad Agency...